ERYTECH confirme son intention de déposer une demande de BLA pour eryaspase dans le traitement des patients atteints de LAL hypersensible

NEXT STORY
Eldorado Gold Acquires Shares of Probe Metals Inc.
PREV STORY
Grey Stone Labs In Texas: New Career Opportunities Available
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Breathtec Provides Nash Pharmaceuticals’ Plans for Next Year

VANCOUVER, British Columbia, Sept. 13, 2018 (GLOBE NEWSWIRE) -- Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI) ...

author_avatar
NASDAQ Market News

ChemoCentryx Reports Third Quarter 2018 Financial Results and Recent Highlights

-- Large, controlled clinical trial of avacopan in Hidradenitis Suppurativa (HS) on track to ...

author_avatar
NASDAQ Market News

PDC Healthcare Introduces New Line of Spee-D-Mark™ 3D Breast Tomosynthesis Markers for Mammography

VALENCIA, Calif., Oct. 31, 2017 (GLOBE NEWSWIRE) -- PDC Healthcare, a global leader of ...

author_avatar
NASDAQ Market News